← Leaderboards
Ian Christopher Davis
University Of Alabama At Birmingham
$6,632,717
Attributed
$7,439,718
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $991.5K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,439,718 · 6
By mechanism
R01$4,406,486 · 2
U01$1,614,003 · 1
R21$881,395 · 2
K01$537,834 · 1
Top collaborators
- Elliott D Crouser3 shared
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Sadis Matalon$21,362,558
- Michael B Fallon$7,992,553
- Vytas A Bankaitis$16,946,786
- Hong-Long Ji$5,013,833
- Elizabeth A Gardner$50,000
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsHypoxemiaInfectionLungAlveolar Type Ii CellCessation Of LifeInfluenza A VirusVirusVirus DiseasesIon TransportPathogenesisCell PhysiologyAcuteViralInfluenzaFunctional DisorderInfluenza EpidemicSeasonal InfluenzaAttenuatedCombatPhospholipidsGenerationsC57bl/6 MouseLife
Grant awards (19)
PB1-F2 mediates hypoxemia in influenza$433,125
R21 · FY2025 · AI · contact PI
Supplemental Citicoline Administration for Reduction of Lung Injury Efficacy Trial (SCARLET)$494,210
U01 · FY2024 · AI
Supplemental Citicoline Administration for Reduction of Lung Injury Efficacy Trial (SCARLET)$543,218
U01 · FY2023 · AI
Role of ATII cell senescence in influenza pathogenesis in aging$448,270
R21 · FY2023 · AG · contact PI
Supplemental Citicoline Administration for Reduction of Lung Injury Efficacy Trial (SCARLET)$576,575
U01 · FY2022 · AI
Role of alterations in the ATII cell lipidome in influenza pathogenesis$745,184
R01 · FY2020 · HL · contact PI
Role of alterations in the ATII cell lipidome in influenza pathogenesis$737,880
R01 · FY2019 · HL · contact PI
Role of alterations in the ATII cell lipidome in influenza pathogenesis$543,563
R01 · FY2018 · HL · contact PI
Role of alterations in the ATII cell lipidome in influenza pathogenesis$510,711
R01 · FY2017 · HL · contact PI
The role of adenosine in the pathogenesis of influenza$369,889
R01 · FY2014 · HL · contact PI
The role of adenosine in the pathogenesis of influenza$359,321
R01 · FY2013 · HL · contact PI
The role of adenosine in the pathogenesis of influenza$377,438
R01 · FY2012 · HL · contact PI
The role of adenosine in the pathogenesis of influenza$381,250
R01 · FY2011 · HL · contact PI
The role of adenosine in the pathogenesis of influenza$381,250
R01 · FY2010 · HL · contact PI
Na+ TRANSPORT INHIBITION BY RESPIRATORY SYNCYTIAL VIRUS$120,096
K01 · FY2007 · RR · contact PI
Na+ TRANSPORT INHIBITION BY RESPIRATORY SYNCYTIAL VIRUS$120,096
K01 · FY2006 · RR · contact PI
Na+ TRANSPORT INHIBITION BY RESPIRATORY SYNCYTIAL VIRUS$57,450
K01 · FY2005 · RR
Na+ TRANSPORT INHIBITION BY RESPIRATORY SYNCYTIAL VIRUS$120,096
K01 · FY2004 · RR
Na+ TRANSPORT INHIBITION BY RESPIRATORY SYNCYTIAL VIRUS$120,096
K01 · FY2003 · RR